everyone. Jill, you, good Thank and morning,
trial in study. As you, final for global is PolarisDMD X edasalonexent and preparations multi-centered a soon begin are Jill told enrollment underway Duchenne. PolarisDMD Phase will our with
Australia, sites Europe three enrollment U.S. in the start Canada, trial Israel, with to the States, about first at clinical sites dozen United and across expect We
trial. we mentioned, to Jill activities As the all great progress made in initiate the
We available. have edasalonexent drug
submitted approval we We and in IRB several have finalized have protocol it to sites review the we institutional and actually the for boards U.S.
randomized double-blind PolarisDMD trial placebo-controlled is XXX enroll a soon sharing expected be is boys. sites updates for first will open to We as the and enrollment. approximately
Boys we PolarisDMD are boys MoveDMD X X aged on have Phase because was who that and others will of we otherwise our trial. early were provide of Xth boys edasalonexent declining benefit. study will the for As X efficacy steroids the EXONDYS trial score Star not age-appropriate And boys our who with be birthday. in the edasalonexent function we XX, of primary range randomization in regardless have potential a change tests placebo. will stable stand, X-stair boys enroll milligrams kilogram secondary X, age type, Ambulatory months. X, include XXX The treatment will months will mutation X endpoint shown, placebo. to did be their of functional as The not Key taken can the largest This believe such per past to enroll that in walk/run. include edasalonexent, X that to to their receive receive up Assessment North for chosen, per The in trial, intervention after abilities. every endpoints boy on will dose six time with timed climb will are XX eligible, who day and steroids compared the XX-meter to
edasalonexent our all conferences that continuing making at advance support a We're the improvement appreciate plan and be mission. and the we this edasalonexent milestone, program bone development, all There boys a in have closer extension, upcoming to very our about is from when eager connect of those are a answer also and and two have in Assessments Phase than that trial. cardiac received I scientific want participation [ph] of edasalonexent extension considering their to The as showed those to they the are as included from to ongoing, many We've families boy Thank to and clinical from will families with We're participating edasalonexent the truly get across PolarisDMD care. open-label recently longer measures current well compared X year period the to term open-label their trial differentiators well trial important any families these progress design number also open-label MoveDMD of trial edasalonexent. in trial. The extension. boys, MoveDMD MoveDMD functional are the boys a our step happy parents We're results standard confident hear community, years. the by health additional trial and assess to thrilled for to and that of as where doing of trial partnership present edasalonexent will XXXX. and with making are We the the affected the in particularly the recent the to was conferences turned Duchenne. are and continue to X wonderful and you clinical boys' inquiries as their in associated stage in final later shared of edasalonexent been rewarding We sites to control MoveDMD off-treatment to an advocacy plans to for we feedback and appreciation boys trial these open-label sites, in express Phase their our transition interested more our Duchenne of questions and growth, we and approval clinical receive people one available XX-years-old. from advocacy at the and enthusiasm we MoveDMD as meetings. help see trial.
Duchenne. throughout a broad mutation to now will share I Andy? patient and pass our of call to goal all by a Our update. for the over edasalonexent treat Andy research is will affected who lifetime CSO, population Nichols, those across the types
